Frankfurt Court Upholds BESREMi Arbitral Award Favoring AOP Health Over PharmaEssentia

Key Takeaways

• Frankfurt Higher Regional Court upheld ICC arbitral award favoring AOP Health in BESREMi dispute with PharmaEssentia
• Court confirmed PharmaEssentia liable for damages related to intentional breach of contract
• Ruling strengthens AOP Health’s position in ongoing pharmaceutical licensing dispute

---

The Frankfurt Higher Regional Court has upheld a partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (AOP Health) in its legal dispute with Taiwan-based PharmaEssentia Corp regarding BESREMi, confirming the Taiwanese company’s liability for certain damages.

Court Confirms Arbitral Decision

The ruling validates the February 17, 2025 ICC arbitral award that found PharmaEssentia Corp (PEC) guilty of intentional breach of contract. This decision represents a significant legal victory for AOP Health, an Austrian pharmaceutical company specializing in rare disease treatments.

BESREMi (ropeginterferon alfa-2b) is a long-acting interferon treatment primarily used for polycythemia vera, a rare blood cancer. The drug has been a subject of licensing and commercial disputes between the two pharmaceutical companies.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Legal Background and Implications

The arbitration process began following disagreements between AOP Health and PharmaEssentia over contractual obligations related to BESREMi. The International Chamber of Commerce (ICC) arbitration tribunal initially ruled in February 2025 that PharmaEssentia had intentionally breached its contractual commitments.

PharmaEssentia’s challenge to the arbitral award has now been rejected by the Frankfurt Higher Regional Court, solidifying AOP Health’s legal position. This confirmation means PharmaEssentia remains liable for damages as determined by the original arbitration panel.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

The court’s decision strengthens AOP Health’s commercial position regarding BESREMi and may influence future licensing agreements in the rare disease pharmaceutical sector. For patients relying on BESREMi treatment, the ruling provides clarity on the drug’s commercial stability and continued availability through AOP Health’s distribution channels.

The pharmaceutical industry closely watches such arbitration cases as they set precedents for international licensing disputes and contractual enforcement in the specialized rare disease market.

---

Frequently Asked Questions

What is BESREMi and what does it treat?

BESREMi (ropeginterferon alfa-2b) is a long-acting interferon treatment primarily used for polycythemia vera, a rare blood cancer that causes the body to produce too many red blood cells.

How does this ruling affect BESREMi availability for patients?

The ruling confirms AOP Health’s legal position and should not negatively impact BESREMi availability. Patients can continue accessing the treatment through established AOP Health distribution channels.

What was the dispute between AOP Health and PharmaEssentia about?

The dispute centered on contractual obligations related to BESREMi, with the ICC arbitration finding that PharmaEssentia intentionally breached its contract with AOP Health, resulting in damages.